Compare Epigenesis Pharmaceuticals vs Knopp Biosciences
Customers evaluate the quality of Epigenesis Pharmaceuticals's products using the following success metrics.
Overview
Epigenesis Pharmaceuticals is 29 yrs old and is based in United States.
EpiGenesis Pharmaceuticals is a drug discovery and development company focused on respiratory disease. The company has a candidate for asthma, EPI 12323, which is an inhaled steroid with properties and early indications that it could outperform current steroid treatments on the market.
Knopp Biosciences is 20 yrs old and is based in United States.
Knopp Biosciences is a privately held company that operates in the pharmaceutical industry, focusing on drug discovery in immunological and neurological diseases. The company's main offerings include the development of oral small molecules for the treatment of conditions such as eosinophilic asthma and hyperexcitability disorders. The company primarily serves the healthcare sector. It was founded in 2004 and is based in Pittsburgh, Pennsylvania.
Demo Video
Leadership
Jonathan Nyce (Chief Executive Officer)
Gregory T. Hebrank (Executive Vice President)
Investors
Care Capital, Boston Millennia Partners
National Institutes of Health, Pilot House Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Epigenesis Pharmaceuticals has not claimed their profile.
Work for Epigenesis Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Epigenesis Pharmaceuticals?
Claim your profile now.
Information not available because Knopp Biosciences has not claimed their profile.
Work for Knopp Biosciences? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Knopp Biosciences?
Claim your profile now.